Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Junmaikang (adalimumab) in Chinese pediatric chronic severe plaque psoriasis
CTR20242789Phase 4Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in psoriasis, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jul 2024; status: active.
02
Drugs
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20242789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242789.